Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Ezra Cohen, MD
Advertisement
Articles by Ezra Cohen, MD
Advertisement
Latest Updated Articles
Immunotherapeutic Approaches to the Management of Head and Neck CancerDecember 17th 2018
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
4
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
5